Neurotoxins: Expanding Uses of Neuromodulators in Medicine—Major Depressive Disorder

@article{Magid2015NeurotoxinsEU,
  title={Neurotoxins: Expanding Uses of Neuromodulators in Medicine—Major Depressive Disorder},
  author={Michelle Magid and Brett H. Keeling and Jason S. Reichenberg},
  journal={Plastic and Reconstructive Surgery},
  year={2015},
  volume={136},
  pages={111S–119S}
}
Background: Botulinum toxin A (BTA) is one of the most diversely used medications of the 21st century and is now being researched as a treatment for major depressive disorder (MDD). Methods: The authors performed a literature search of PubMed, Web of Science, and the Cochrane Register of Controlled Trials. The primary investigators of the studies were contacted for additional unpublished data. Results: The authors identified 5 studies that met the criteria of using BTA in the treatment of MDD… 
10 Citations
Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
TLDR
Evidence is provided that BTX-A injections are associated with a statistically significant improvement in depressive symptoms and may provide a new, alternative option for the treatment of depression.
Does Blocking Facial Feedback Via Botulinum Toxin Injections Decrease Depression? A Critical Review and Meta-Analysis
Researchers have proposed that blocking facial feedback via glabellar-region botulinum toxin injections (GBTX) can reduce depression. Random-effects meta-analyses of studies that administered GBTX to
Pharmacology of Neurotoxins: Onabotulinum Toxin (Botox®), Abobotulinum Toxin (Dysport®), Incobotulinum Toxin (Xeomin®), and Prabotulinumtoxin-xvfs (Jeuveau™)
  • B. Haney
  • Medicine
    Aesthetic Procedures: Nurse Practitioner's Guide to Cosmetic Dermatology
  • 2019
TLDR
The pharmacology of the most commonly used neurotoxins for cosmetic use is reviewed, which results in relaxation of the targeted muscle or muscle group and leads to smoother overlying skin because the muscle is no longer able to fully contract and cause a line.
The non‐neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond
TLDR
BoNTs have a much wider range of applications than originally understood, and the individual cellular responses to the cholinergic impacts of BoNTs could provide fertile ground for future studies.
Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies.
TLDR
The prevention and treatment of adverse events, therapeutic and novel aesthetic indications, controversies, and a brief overview of combination therapies are reviewed.
Patient Satisfaction and Patients' Family or Significant Other Perceptions After OnabotulinumtoxinA Treatment: A Prospective Cross-Sectional Study.
  • J. Montes, Ruhi V. Ubale
  • Medicine
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2019
TLDR
OnabotulinumtoxinA treatment is one of the most precise and predictable cosmetic treatments available, with high patient satisfaction, and was the appreciation and acceptance by those in close contact with them.
Horizontal Gene Transfer Between Bacteriophages and Bacteria: Antibiotic Resistances and Toxin Production
TLDR
The role of bacteriophages in the transfer of both antibiotic resistance genes and genes encoding novel toxins to new bacterial species is focused on.
Psychological Aspects of Aesthetics
  • B. Haney
  • Psychology
    Aesthetic Procedures: Nurse Practitioner's Guide to Cosmetic Dermatology
  • 2019
The notion of beauty is as varied as the individual patient. What one person perceives as attractive may be unsightly to another. Trust in the practitioner to provide an aesthetic outcome that

References

SHOWING 1-10 OF 59 REFERENCES
Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials.
TLDR
Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD.
Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
TLDR
Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD.
Agitation Predicts Response of Depression to Botulinum Toxin Treatment in a Randomized Controlled Trial
TLDR
Data provide a link between response to botulinum toxin treatment with a psychomotor manifestation of depression and thereby indirect support of the proposed facial feedback mechanism of action and suggests that patients with agitated depression may particularly benefit from botulinUM toxin treatment.
Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.
TLDR
A single treatment with OBA to the corrugator and procerus muscles appears to induce a significant and sustained antidepressant effect in patients with major depression.
Antidepressant effects of botulinum toxin A: scientific rationale.
  • E. Finzi
  • Psychology, Medicine
    Journal of psychiatry & neuroscience : JPN
  • 2013
TLDR
The first to show that botulinum toxin A could be used as an antidepressant by inhibiting frowning in patients with major depression and the complete resolution of the omega melancholium sign in a patient after treatment with botulinu toxin A is shown.
Facing depression with botulinum toxin: a randomized controlled trial.
TLDR
This study shows that a single treatment of the glabellar region with botulinum toxin may shortly accomplish a strong and sustained alleviation of depression in patients, who did not improve sufficiently on previous medication.
Treatment of Depression with Botulinum Toxin A: A Case Series
  • E. Finzi, Erika L. Wasserman
  • Medicine
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2006
TLDR
These are the first reported cases of depression treated with botulinum toxin A in treating patients with major depression, and 9 of 10 patients were no longer depressed 2 months after treatment.
10 Recent Paradigm Shifts in the Neurobiology and Treatment of Depression
TLDR
Three landmark studies have demonstrated that a single IV dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine can produce clinical improvement of severe depression and even full remission for several days, demonstrating that the old dogma of 5-HT and NE deficiency might not be a valid overarching hypothesis of the depression syndrome.
Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
TLDR
Possible mechanisms to explain how onabotulinumtoxinA functions as a therapy for chronic migraine are described and why treatment with the neurotoxin is not effective in some chronic migraineurs are considered.
Fluoxetine versus other types of pharmacotherapy for depression.
TLDR
Fluoxetine was as effective as the TCAs when considered as a group both on a dichotomous outcome and when dropouts were excluded from any assessment in the primary studies, they were considered as treatment failures.
...
1
2
3
4
5
...